Cemiplimab in metastatic or unresectable NUT carcinoma (Northwestern pilot)
The first dedicated immunotherapy trial in NUT carcinoma, asking whether a PD-1 antibody can do anything in a cancer that chemotherapy rarely controls.
Overview
Case reports have described occasional responses of NUT carcinoma to checkpoint inhibitors despite its low mutation burden. This Northwestern University pilot gives cemiplimab to fifteen patients with metastatic or unresectable disease and measures safety and clinical activity. It is recruiting.
Similar pages
not linked directly; found by shared links- TrialZEN-3694 with abemaciclib in NUT carcinoma, breast cancer and other solid tumours (NCI phase 1)
Shares NUT carcinoma (midline carcinoma with NUTM1 rearrangement) and the tag owner-request.
- TrialZEN-3694 with platinum chemotherapy in NUT carcinoma (NCI phase 1/2)
Shares NUT carcinoma (midline carcinoma with NUTM1 rearrangement) and the tag owner-request.
- TreatmentZEN-3694
Shares NUT carcinoma (midline carcinoma with NUTM1 rearrangement) and the tag owner-request.
- TrialPembrolizumab with or without anetumab ravtansine in mesothelin-positive pleural mesothelioma (NCI)
Shares Immune checkpoint inhibitors and the tag owner-request.
- CancerSkin cancer (all types)
Shares Cemiplimab, Immune checkpoint inhibitors.
- TreatmentFianlimab
Shares Cemiplimab, Immune checkpoint inhibitors.
- CancerVulvar cancer
Shares Cemiplimab, Immune checkpoint inhibitors.
- CancerPenile cancer
Shares Cemiplimab, Immune checkpoint inhibitors.